Press Releases
Aitia Appoints Drug R&D Executive Jean-Michel Gries as President & Chief Operating Officer
Aitia, the leader in the development and application of Causal AI and Digital Twins to discover and develop new drugs, today announced the appointment of Dr. Jean-Michel Gries as President & Chief Operating Officer.
Alzheimer’s Disease Mechanistic Pathways Discovered through Aitia’s Digital Twins and in silico Experiments in Causal AI to be Presented at AAIC 2023
Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its Alzheimer’s Disease Digital Twins will be presented at the upcoming Alzheimer’s Association International Conference (AAIC).
Aitia Enters into Multi-Year AI-Driven Drug Discovery and Drug Simulation Collaboration with Servier for Pancreatic Cancer
Aitia, the leader in the development and application of Causal AI and “Digital Twins” to discover and develop new drugs, today announced a collaboration with Servier to create new Gemini Digital Twins to help in the fight against Pancreatic Cancer.
Demonstration of Accurate Screening of Gene Dependency in Multiple Myeloma from Aitia’s Gemini Digital Twins to be Presented at 2023 AACR Annual Meeting
Aitia, the leader in the application of causal AI and “Digital Twins” to discover and develop new drugs, announced today that data from its Multiple Myeloma Digital Twin model will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting.
Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington’s Disease
UCB, a global biopharmaceutical company, and Aitia, the leader in the application of Causal AI and “Digital Twins” to discover and develop new drugs, today announced an early drug discovery collaboration focused on the discovery and validation of novel drug targets and drug candidates for Huntington’s disease.
Aitia and G3 Therapeutics Publish Results Identifying New Causal Biomarkers of Atherosclerotic Coronary Artery Disease (ASCAD), the Leading Cause of Morbidity and Mortality Worldwide
G3 Therapeutics, a life sciences company that leverages large-scale multi-omic biological big data to develop life-changing therapeutics and diagnostics, and Aitia, the leader in the application of Causal AI and “Digital Twins” to discover and develop new drugs, today announced results of research that identified new causes of ASCAD.
GNS Rebrands as Aitia to Focus on AI-Enabled Drug Discovery
GNS, the leader in the application of causal AI and “Digital Twins” to discover and develop new drugs, announced today its rebranding as Aitia (pronounced “ay-tee-ah”). Aitia, derived from the Greek word for causality, will focus on further leveraging its Gemini Digital Twins to discover the next generation of breakthrough drugs to improve outcomes for patients…
GNS Announces Abstract and Oral Poster Presentation at CTAD & ASH, 2022 Annual Conferences
GNS, the leader in the application of Causal AI and simulation and “Digital Twins” to discover new drugs, today announced two abstracts and two oral poster presentations highlighting insight from the Gemini Digital Twin models in Alzheimer’s Disease and Multiple Myeloma will be included at the Clinical Trials on Alzheimer’s Disease conference (CTAD) in San Francisco and the American Society of Hematology (ASH) in New Orleans…
GNS Appoints John Maraganore as Chair of the Board
GNS, the leader in the application of Causal AI and simulation and “Digital Twins” to discover new drugs, today announced that John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, has been appointed as the new GNS Chair of the Board…
GNS and Servier Announce AI Collaboration to Advance Multiple Myeloma Drug Discovery and Clinical Development
GNS and Servier, today announced a collaboration to advance drug discovery, translational, and clinical development efforts in Multiple Myeloma (MM).